Astex Announces Commencement of Phase I Study for AZD5363 in Anti-Cancer Collaboration with AstraZeneca Cambridge, UK, 12th April[removed]Astex Therapeutics, the UK-based biotechnology company developing targeted therapies

First Page		Document Content
Institute of Cancer Research AstraZeneca Cancer research AKT Pharmaceutical industry London Astex Medicine Pharmaceutical sciences		Astex Announces Commencement of Phase I Study for AZD5363 in Anti-Cancer Collaboration with AstraZeneca Cambridge, UK, 12th April[removed]Astex Therapeutics, the UK-based biotechnology company developing targeted therapies Add to Reading List Source URL: astx.com Download Document from Source Website File Size: 11,88 KB Share Document on Facebook

	PDF Document DocID: 1xtSy - View Document
	PDF Document DocID: 1x8mY - View Document
	PDF Document DocID: 1wOXw - View Document
	PDF Document DocID: 1wJ3B - View Document
	PDF Document DocID: 1wie6 - View Document